Drugplain

Caffeine and Sodium Benzoate 125 mg/mL

Caffeine and Sodium Benzoate · INJECTION, SOLUTION · American Regent, Inc.

No Recall History
Plain English

Caffeine and Sodium Benzoate is a injection, solution containing caffeine and sodium benzoate at 125 mg/mL, taken intramuscular. Manufactured by American Regent, Inc..

Key Facts

Brand Name
Caffeine and Sodium Benzoate
Generic Name
Caffeine and Sodium Benzoate
NDC Code (Product)
0517-2502
Manufacturer
American Regent, Inc.
Strength
125 mg/mL
Dosage Form
INJECTION, SOLUTION
Route
INTRAMUSCULAR, INTRAVENOUS
Marketing Status
Drug Class
Central Nervous System Stimulant [EPC]; Methylxanthine [EPC]
Marketing Start
02/01/1993

Recall History

No Recall History

Side Effects Reported to FDA

FDA FAERS database · These are reported events, not confirmed side effects

blood pressure decreased2 reports
cardiac arrest2 reports
circulatory collapse2 reports
malaise2 reports
nausea2 reports
overdose2 reports
product label issue2 reports
product preparation error2 reports
suicide attempt2 reports
anaemia1 reports

Full Prescribing Information

Source: FDA Drug Label (SPL)For healthcare professionals

Indications & Usage

INDICATIONS AND USAGE Caffeine and Sodium Benzoate Injection has been used in conjunction with supportive measure to treat respiratory depression associated with overdosage with CNS depressant drugs (e.g., narcotic analgesics, alcohol). However, because of questionable benefit and transient action, most authorities believe caffeine and other analeptics should not be used in these conditions and recommend other supportive therapy.

Dosage & Administration

DOSAGE AND ADMINISTRATION Caffeine and Sodium Benzoate Injection may be administered by intramuscular or slow intravenous injection. Some clinicians suggest that when used as a mild CNS stimulant to overcome fatigue, oral doses of 100-200 mg of anhydrous caffeine are required. One manufacturer recommends that citrated caffeine be administered orally in dosages of 65-325 mg (about 32-162 mg of anhydrous caffeine) 3 times daily. Another manufacturer recommends an oral dosage of 250 mg of anhydrous caffeine in an extended-release formulation once daily, but warns that the drug should not be administered less than 6 hours before retiring. Analeptic use of caffeine is strongly discouraged by most clinicians. However, the manufacturer of Caffeine and Sodium Benzoate Injection recommends intramuscular, or in emergency respiratory failure, intravenous injection of 500 mg of the drug (about 250 mg of anhydrous caffeine) or a maximum single dose of 1 gram (about 500 mg of anhydrous caffeine) for the treatment of respiratory depression associated with overdosage of CNS depressants, including narcotic analgesics and alcohol, and with electric shock. The usual dose is 0.5 g (7 ½ grains) as freq

Contraindications

CONTRAINDICATIONS None known.

Frequently Asked Questions

What is Caffeine and Sodium Benzoate used for?

Caffeine and Sodium Benzoate contains Caffeine and Sodium Benzoate. It is a injection, solution taken intramuscular. Consult your doctor for specific uses.

Is Caffeine and Sodium Benzoate a controlled substance?

Caffeine and Sodium Benzoate is not classified as a controlled substance by the DEA.

What is the generic name for Caffeine and Sodium Benzoate?

The generic name for Caffeine and Sodium Benzoate is Caffeine and Sodium Benzoate. There are no other listed brand versions of Caffeine and Sodium Benzoate.

What is the NDC code for Caffeine and Sodium Benzoate 125 mg/mL?

The NDC (National Drug Code) for Caffeine and Sodium Benzoate 125 mg/mL is 0517-2502, listed by American Regent, Inc..

Product NDC

0517-2502

Package NDC

0517-2502-10

Not medical advice. Always consult your doctor or pharmacist before making any medication decisions.

Data from openFDA · Public domain (CC0 1.0)